Canine Arthritis Treatment Market – By Treatment Type (Drugs {NSAIDs}, Supplements {Glucosamine}, Surgical Procedures), Arthritis Type (Osteoarthritis, Osteochondrosis, Rheumatoid Arthritis, Traumatic Arthritis), Global Forecast (2024 – 2032)

Canine Arthritis Treatment Market Size

Canine Arthritis Treatment Market size was valued at USD 2.4 billion in 2023 and is anticipated to register a CAGR of over 4.7% between 2024 and 2032, driven by the growing prevalence of arthritis and related disorders among canines.
 

Arthritis is one of the most common chronic conditions affecting dogs, particularly as they age or due to genetic predispositions. Factors such as obesity, joint injuries, and certain breeds' susceptibility contribute to the increasing incidence of arthritis in dogs. Additionally, improved awareness and early diagnosis of arthritis by veterinarians and pet owners have led to more dogs receiving treatment for the condition, thereby augmenting the market growth during the analysis period.
 

Canine arthritis treatment aims to manage pain, reduce inflammation, improve joint function, and enhance the overall quality of life for affected dogs. Treatment options may vary depending on factors such as the severity of the arthritis, the dog's age, breed, size, and overall health condition.
 

Canine Arthritis Treatment Market Trends

• The global market for canine arthritis treatments is being driven by a growing awareness pertaining to their pet health and pet care. Globally, the number of disease cases in dogs and cats has increased recently. It involves decreased appetite, allergies, arthritis, dysplasia, and behavioral anxiety in animals. This factor is emphasizing the need for novel drugs and treatment to eliminate the possibility of canine arthritis in animals. However, high cost of treatment may hamper the market growth to certain extent.
   

Canine Arthritis Treatment Market Analysis

The market based on treatment type is segmented into drugs, supplements, surgical procedures, and other treatment types. The drugs treatment type accounted for majority of market share of 42.3% in 2023.
 

• Drugs offer effective relief from pain and inflammation associated with canine arthritis. Drugs such as non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, and corticosteroids have demonstrated efficacy in alleviating symptoms and improving joint function in arthritic dogs.
   
• Further, ongoing research and development efforts have led to the introduction of new and improved drugs for treating canine arthritis. Pharmaceutical companies are investing in the development of novel drug formulations, delivery systems, and therapeutic targets to enhance the efficacy and safety of arthritis medications for dogs.
   

The canine arthritis treatment market based on arthritis type is classified into osteoarthritis, osteochondrosis, rheumatoid arthritis, and traumatic arthritis. The osteoarthritis segment is expected to reach USD 1.4 billion by 2032.
 

• Osteoarthritis is more prevalent in older dogs, and therefore the aging pet demographic contributes to the overall increase in osteoarthritis cases. The rise in pet obesity is a significant contributor to the increase in osteoarthritis cases among canines. Excess body weight places additional strain on the joints, leading to accelerated wear and tear and an increased risk of developing osteoarthritis.
   

North America canine arthritis treatment market accounted for USD 1 billion market revenue in 2023 and is anticipated to grow at CAGR of 4.6% between 2024 – 2032 period.
 

• Adoption of companion animal, growing prevalence of canine arthritis, and rise in per capita animal healthcare expenditure in the region is expected to supplement the market growth. According to the American Pet Products Association's 2021-2022 National Pet Owners Survey, 54% of households in the U.S. have pet dogs. Thus, increasing number of pet owners coupled with increasing awareness regarding their proper health is projected to accelerate the regional expansion.
   

Canine Arthritis Treatment Market Share

The canine arthritis treatment industry is characterized by the presence of several key players offering innovative solutions. The strategic partnerships, mergers, and acquisitions are common strategies employed by players to expand their market presence, enhance their product portfolios, and gain a competitive advantage.
 

Canine Arthritis Treatment Market Companies

Prominent players operating in the canine arthritis treatment industry include:

• American Regent, Inc.
• Bayer AG
• Boehringer Ingelheim Animal Health
• CEVA Santé Animale
• Dechra Pharmaceuticals PLC
• Elanco Animal Health
• Nutramax Laboratories Veterinary Sciences, Inc.
• Vetoquinol SA
• VetStem, Inc.
• Virbac
• Zoetis Inc.
   

Canine Arthritis Treatment Industry News:

• In May 2023, Zoetis received approval from the U.S. Food and Drug Administration (FDA) for Librela (bedinvetmab injection) to manage osteoarthritis (OA) pain in dogs. Librela is a once-monthly anti-nerve growth factor (NGF) monoclonal antibody treatment designed to alleviate pain associated with canine OA. This approval marks a significant advancement in pain management for dogs, offering a safe and effective long-term solution that can enhance their mobility, thereby strengthening its product line.
   

The canine arthritis treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Drugs
  • Non-steroidal anti-inflammatory drugs (NSAID’s)
  • Corticosteroids
  • Opioid pain relievers
  • Other drugs 
• Supplements
  • Glucosamine
  • Chondroitin
  • Methylsulfonylmethane
  • Other supplements
  • Drugs and supplements market, by route of administration
    • Oral
    • Injectable
    • Other routes of administration
• Drugs and supplements market, by distribution channel
  • Veterinary hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
• Surgical procedures
• Other treatment types

Market, By Arthritis Type

• Osteoarthritis
• Osteochondrosis
• Rheumatoid arthritis
• Traumatic arthritis

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East and Africa